New Results add to Growing Body of Evidence That Support Bendamustine-rituximab (B-R) Combination as First-Line Treatment in Patients With Indolent non-Hodgkin (iNHL) and Mantle Cell Lymphomas (MCL)

New Results add to Growing Body of Evidence That Support Bendamustine-rituximab (B-R) Combination as First-Line Treatment in Patients With Indolent non-Hodgkin (iNHL) and Mantle Cell Lymphomas (MCL) PR Newswire CAMBRIDGE, England, December 11, 2012 CAMBRIDGE, England, December 11, 2012 /PRNewswire/ -- FOR MEDICAL MEDIA ONLY – NOT INTENDED FOR FRENCH MEDIA Data demonstrate superior patient outcomes with B-R in first-line treatment of iNHL and MCL, compared with current standard of care thFive sets of new data analyses presented this week at the 54 annual meeting of the American Society of Hematology (ASH) in Atlanta, Georgia, show that a first-line treatment regimen of bendamustine plus rituximab (B-R) results in superior patient outcomes compared with current standard of care, CHOP-R/CVP-R, in patients with indolent non- [1],[2],[3],[4],[5]Hodgkin lymphomas (iNHL) and mantle cell lymphomas (MCL). A sub-analysis of the StiL NHL 1-2003 Study, demonstrated significantly prolonged progression free survival (PFS) and overall survival (OS) for iNHL and MCL patients who achieved a complete response (CR) compared with a partial [1]response (PR), irrespective of whether they received B-R or CHOP-R treatment. A CR was observed in a higher [1]proportion of patients treated with B-R (39.8%) vs. those treated with CHOP-R (30.0%).